Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Finished

PanThera Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation

Coordinator
College De France, France
Runs
1 October 2022 to 31 March 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069281

What the project is doing

In the project's own words, from its summary on CORDIS.

Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.

Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.

Topics

Who is involved

OrganisationCityCountryRole
College De FranceParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI